RSV vaccines have reportedly fallen since U.S. regulators narrowed the recommended age range and frequency for the shots.

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ...

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

Emmetrope Ophthalmics, LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today ...

Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...

RSV and the common cold both cause symptoms of viral infection. Coughing tends to be more severe in RSV. Learn how RSV vs.

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...

In 2023, YKHC was able to administer the first doses of a new immunization for RSV: a monoclonal antibody treatment called nirsevimab. It’s meant to help protect infants from severe illness or ...

Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV Vaccine showed 82.6% overall ... The most frequently observed solicited adverse events ...